Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD
| Autor: | Douglas Kelsey, Virginia K. Sutton, Lenard A. Adler, Rosalie Bakken, Frederick W. Reimherr, Anthony Dietrich, Leslie V M Taylor, Albert J. Allen |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Nausea Sexual Behavior Atomoxetine Hydrochloride Xerostomia Drug Administration Schedule law.invention Randomized controlled trial Double-Blind Method Erectile Dysfunction law Sleep Initiation and Maintenance Disorders Surveys and Questionnaires medicine Attention deficit hyperactivity disorder Humans Psychiatry Adverse effect Adrenergic Uptake Inhibitors Propylamines Atomoxetine General Medicine Middle Aged medicine.disease Psychiatry and Mental health Erectile dysfunction Tolerability Attention Deficit Disorder with Hyperactivity Female medicine.symptom Psychology medicine.drug Atomoxetine hydrochloride |
| Zdroj: | Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. 18(2) |
| ISSN: | 1040-1237 |
| Popis: | Attention-Deficit/Hyperactivity Disorder (ADHD) is a disorder characterized by hyperactivity, impulsiveness, and inattention that affects 4% of adults. Atomoxetine hydrochloride is an FDA-approved treatment for adult ADHD, but no studies have clarified whether there are advantages to once versus twice daily dosing.This randomized, double-blind, multicenter study compared safety and tolerability of 80 mg atomoxetine QD versus 40 mg atomoxetine BID in 218 adults with ADHD. Treatment-emergent adverse events (TEAEs), laboratory values, vital signs, weight, electrocardiograms, scores on the Arizona Sexual Experiences Scale, and efficacy (using the Conners' ADHD Rating Scale-Investigator Rated: Screening Version) were assessed.The overall incidence for any one TEAE was low. There was no significant treatment group difference in likelihood of patients experiencing/=1 of the four most commonly observed TEAEs (dry mouth, insomnia, nausea, and erectile dysfunction). Frequency of nausea was significantly lower in the 40 mg BID group (16.4%) than the 80 mg QD group (32.4%; p = .007). There were no unexpected safety results. Although both QD and BID treatments were efficacious, the reduction in scores was greater for BID treatment.Data indicate both dosing strategies are safe, well tolerated, and efficacious in the treatment of adult ADHD. Changes in dosing strategy are unlikely to be accompanied by safety risks, implying that there is room for prescribers to use discretion and to base dosing strategies on individual factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|